ICOS: Reducing First, Subsequent, and Total CV Events in Dyslipidemia Management

To explore how ICOS can assist your CV patients and connect you with a medical rep, please tick the box below:

I acknowledge that my contact details may be used for this purpose*

GGI-CO-A1-AQS-300040480-ELC-H24-1451
IPE: Icosapent ethyl; AHA: American Heart Association (AHA) Science Advisory 2020; NLA: National Lipid Association (NLA) Scientific Statement 2019; T2DM: Type 2 diabetes; CAD: Coronary Artery Disease; TG: Triglyceride; CVD: Cardiovascular Diseases; CV: Cardiovascular; LDL-C: Low-density lipoprotein-cholesterol
Reference: *Prescribing information of ICOS, generated & latest modified on June 2023. 1. Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, May HT, Shaikh K, Shekar C, Roy SK, Tayek J, Nelson JR. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020 Oct 21;41(40):3925-3932. doi: 10.1093/eurheartj/ehaa652. PMID: 32860032; PMCID: PMC7654934.

Persistent CV Risk in Elevated Triglycerides Despite Statin Therapy: ICOS Solution

Mr. Basu’s case: a 54-year-old patient with diabetes, hypertension, and hyperlipidemia on statins, evaluated with...

Explore Venu’s journey on statin therapy, where ICOS showed a 25% risk reduction in 5-Point...

Discover how ICOS, an NLA and AHA-endorsed option, supports improved CV outcomes in patients with...

Heart Meds Cut Risks, Spark GI Issues Now!

@media (max-width:992px) and (min-width:768px) {}         @media (max-width:767px)...